Lakefront Biotherapeutics Financials
LKFT.XAMS
All currency values in € millions unless otherwise noted
| Income Statement | TTM | DEC 2025 |
|---|---|---|
| Revenues | ||
| Revenue | €991 | €1,112 |
| Cost of Revenue | €25 | €30 |
| Gross Profit | €965 | €1,083 |
| Total Operating Expenses | €355 | €581 |
| Operating Income | €610 | €501 |
| Non-Operating | ||
| Net Interest Expense | – | -€2 |
| Income Tax Expense | -€17 | -€19 |
| Net Income | ||
| Net Income | €597 | €321 |
| Per Share Data | ||
| Revenue Per Share | €15.04 | €16.88 |
| EPS (Basic) | €9.06 | €4.87 |
| EPS (Diluted) | €9.06 | €4.87 |
| Shares Outstanding | 65.9M | 65.9M |
Lakefront Biotherapeutics (LKFT.XAMS) financials: revenue, profit and margins
Lakefront Biotherapeutics (LKFT.XAMS) generated about €991 million in revenue and €597 million in net income (a 60.2% net margin) over the trailing twelve months. Figures are from company filings; this is analysis, not investment advice.
Frequently asked
What is Lakefront Biotherapeutics's (LKFT.XAMS) revenue?+
Lakefront Biotherapeutics generated about €991 million in revenue over the trailing twelve months. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Is Lakefront Biotherapeutics profitable?+
Yes, Lakefront Biotherapeutics reported about €597 million in net income over the trailing twelve months, a net profit margin of roughly 60.2%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
What are Lakefront Biotherapeutics's profit margins?+
Lakefront Biotherapeutics runs a gross margin of about 97.5%, an operating margin of about 61.6%, a net margin of about 60.2%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
Peers
Biotechnology · Pick stocks to compare with LKFT.XAMS
Held by ETFs
LKFT.XAMS is in 10 US ETFs. The largest of them, with LKFT.XAMS's weight in each:
Vanguard FTSE Europe ETFVGK0.01%of the fund
Vanguard FTSE All-World ex-US Small-Cap Index FundVSS0.04%of the fund
iShares Core MSCI Europe ETFIEUR0.01%of the fund
Schwab International Small-Cap Equity ETFSCHC0.06%of the fund
SPDR S&P International Small Cap ETFGWX0.08%of the fund
State Street SPDR Portfolio Europe ETFSPEU0.01%of the fund
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing LKFT.XAMS
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.